Molecular Pharmacology and Physiology
USF Health � College of Medicine
Login here to update your profile  
My Profile

Juan Sanchez-Ramos , MD, PhD
Administrative Appointment: Endowed Chair
Primary Department: COLLEGE OF MEDICINE NEUROLOGY

Professor
COLLEGE OF MEDICINE MOLECULAR PHARMACOLOGY & PHYSIOLOGY

Professor
COLLEGE OF MEDICINE NEUROLOGY
profile Image
Contacts
Email: jsramos@health.usf.edu
Phone: (813) 974-5841
Office: FOB, 4105
Mailing address 13320 Laurel Drive
Tampa, FL 33612
View My C.V.
 
Education
  • MD, Medicine, University Of Illinois , Chicago, United States - 1981.
    		•
  • PhD, Pharmacology and Physiology, University of Chicago ,USA - 1976.
    		•
  • PHD, University Of Chicago* , United States - 1976.
    		•
     
    Interdisciplinary & Emerging Signature Programs
    Neuroscience.
     
    Research Summary

    Neurodegeneration, neurotoxicology and adult stem cell biology

     
    Links
    Personal Page:   http://personal.health.usf.edu/jsramos/index%20Neon%20Neurons.htm


    Selected Publications
  • Sanchez-Ramos, J.Song, S.Cao, C.Arendash, G. The potential of hematopoietic growth factors for treatment of Alzheimer's disease: a mini-review. BMC neuroscience. 9 Suppl 2(): S3, 2008.
  • Song, S.Sanchez-Ramos, J. Preparation of neural progenitors from bone marrow and umbilical cord blood. Methods in molecular biology (Clifton, N.J.). 438(): 123-34, 2008.
  • Roscoe, LA.Corsentino, E.Watkins, S.McCall, M.Sanchez-Ramos, J. Well-being of family caregivers of persons with late-stage Huntington's disease: lessons in stress and coping. Health communication. 24(3): 239-48, 2009.
  • Catlow, BJ.Rowe, AR.Clearwater, CR.Mamcarz, M.Arendash, GW.Sanchez-Ramos, J. Effects of environmental enrichment and physical activity on neurogenesis in transgenic PS1/APP mice. Brain research. 1256(): 173-9, 2009.
  • Sanchez-Ramos, J.Song, S.Sava, V.Catlow, B.Lin, X.Mori, T.Cao, C.Arendash, GW. Granulocyte colony stimulating factor decreases brain amyloid burden and reverses cognitive impairment in Alzheimer's mice. Neuroscience. 163(1): 55-72, 2009.
  • Apostolatos, H.Apostolatos, A.Vickers, T.Watson, JE.Song, S.Vale, F.Cooper, DR.Sanchez-Ramos, J.Patel, NA. Vitamin A metabolite, all-trans-retinoic acid, mediates alternative splicing of protein kinase C deltaVIII (PKCdeltaVIII) isoform via splicing factor SC35. The Journal of biological chemistry. 285(34): 25987-95, 2010.
  • Arendash, GW.Sanchez-Ramos, J.Mori, T.Mamcarz, M.Lin, X.Runfeldt, M.Wang, L.Zhang, G.Sava, V.Tan, J.Cao, C. Electromagnetic field treatment protects against and reverses cognitive impairment in Alzheimer's disease mice. Journal of Alzheimer's disease : JAD. 19(1): 191-210, 2010.
  • Catlow, BJ.Badanich, KA.Sponaugle, AE.Rowe, AR.Song, S.Rafalovich, I.Sava, V.Kirstein, CL.Sanchez-Ramos, J. Effects of MDMA ("ecstasy") during adolescence on place conditioning and hippocampal neurogenesis. European journal of pharmacology. 628(1-3): 96-103, 2010.
  • Song, S.Sava, V.Rowe, A.Li, K.Cao, C.Mori, T.Sanchez-Ramos, J. Granulocyte-colony stimulating factor (G-CSF) enhances recovery in mouse model of Parkinson's disease. Neuroscience letters. 487(2): 153-7, 2011.

    • Grants
  • HUNTINGTON'S DISEASE CLINIC - CENTER OF EXCELLENCE ($50,000.00, 10/01/2004-12/31/2012)
  • RESEARCH ASSOCIATE SERVICES FOR KUNYU LI ($16,000.00, 09/09/2011-09/18/2012)
  • RESEARCH ASSOCIATE SERVICES CHUANHAI CAO ($10,000.00, 08/13/2011-08/12/2012)
  • RESEARCH ASSOCIATE SERVICES FOR AMANDA ROWE ($24,000.00, 08/13/2011-08/12/2012)
  • PROTOCOL #CHDI COGNITIVE ASSESSMENT BATTERY (CAB) ($65,075.00, 01/25/2011-06/30/2012)
  • PROTOCOL # SP953 ($2,630.00, 07/27/2011-05/05/2012)
  • PROTOCOL # SP953 ($1,500.00, 07/27/2011-05/05/2012)
  • DISEASE-MODIFYING EFFECTS OF FILGASTRIM IN A MOUSE MODEL OF AD ($25,000.00, 04/23/2011-04/22/2012)
  • DISEASE-MODIFYING EFFECTS OF FILGASTRIM IN A MOUSE MODEL OF AD ($70,000.00, 04/23/2011-04/22/2012)
  • HUNTINGTON'S DISEASE CLINIC - CENTER OF EXCELLENCE ($25,000.00, 10/01/2004-12/31/2011)
  • HUNTINGTON'S DISEASE CLINIC - CENTER OF EXCELLENCE ($50,000.00, 10/01/2004-12/31/2011)
  • COENZYME Q10 IN HUNTINGTON'S DISEASE ($1,294.00, 12/01/2007-11/30/2011)
  • FUNCTION AND FATE OF NESTIN-EXPRESSING STEM CELLS DERIVED FROM ADULT BRAIN AND BONE MARROW ($14,000.00, 09/09/2010-09/08/2011)
  • DISEASE-MODIFYING EFFECTS OF FILGASTRIM IN A MOUSE MODEL OF AD ($3,000.00, 08/15/2010-08/14/2011)
  • DISEASE-MODIFYING EFFECTS OF FILGASTRIM IN A MOUSE MODEL ($18,000.00, 08/13/2010-08/12/2011)
  • DISEASE-MODIFYING EFFECTS OF FILGASTRIM IN A MOUSE MODEL OF AD ($24,000.00, 08/13/2010-08/12/2011)
  • DISEASE-MODIFYING EFFECTS OF FILGASTRIM IN A MOUSE MODEL OF AD ($10,000.00, 08/13/2010-08/12/2011)
  • DISEASE-MODIFYING EFFECTS OF FILGASTRIM IN A MOUSE MODEL ($21,000.00, 08/13/2010-08/12/2011)
  • COOPERATIVE HUNTINGTON'S OBSERVATIONAL RESEARCH TRIAL ($46,000.00, 07/01/2010-06/30/2011)
  • DISEASE-MODIFYING EFFECTS OF FILGASTRIM IN A MOUSE MODEL OF AD ($15,000.00, 04/23/2010-04/22/2011)
  • PROTOCOL #HART ($19,040.00, 08/15/2008-03/31/2011)
  • HUNTINGTON'S DISEASE CLINIC - CENTER OF EXCELLENCE ($25,000.00, 10/01/2004-12/31/2010)
  • DISEASE-MODIFYING EFFECTS OF FILGASTRIM IN A MOUSE MODEL OF AD ($35,000.00, 04/23/2010-10/22/2010)
  • RESEARCH ASSOCIATE SERVICES FOR KUNYU LI ($13,000.00, 09/09/2009-09/08/2010)
  • VA MERIT AWARD ($100,000.00, 07/01/2009-06/30/2010)
  • CREATINE SAFETY, TOLERABILITY, AND EFFICACY IN HUNTINGTON'S DISEASE: CREST-E ($25,485.00, 07/01/2008-06/30/2010)
  • COOPERATIVE HUNTINGTON'S OBSERVATIONAL RESEARCH TRIAL (COHORT) ($24,000.00, 07/01/2005-06/30/2010)
  • COOPERATIVE HUNTINGTON'S OBSERVATIONAL RESEARCH TRIAL (COHORT) ($16,000.00, 07/01/2005-06/30/2010)
  • PROTOCOL #HART ($96,404.00, 08/15/2008-03/31/2010)
  • RESEARCH ASSISTANT SERVICES FOR AMANDA ROWE ($12,000.00, 09/30/2009-03/29/2010)
  • RESEARCH ASSOCIATE SERVICES FOR VASYL SAVA ($19,000.00, 09/30/2009-03/27/2010)
  • EFFICACY AND SAFETY OF FILGASTRIM (NEUPOGEN) AS A PRO-COGNITIVE AGENT FOR ALZHEIMER'S DISEASE ($137,500.00, 02/01/2009-01/31/2010)
  • EFFICACY AND SAFETY OF FILGASTRIM (NEUPOGEN) AS A PRO-COGNITIVE AGENT FOR ALZHEIMER'S DISEASE ($42,500.00, 02/01/2009-01/31/2010)
  • HUNTINGTON'S DISEASE CLINIC - CENTER OF EXCELLENCE ($50,000.00, 10/01/2004-12/31/2009)
  • COENZYME Q10 IN HUNTINGTON'S DISEASE ($97,500.00, 12/01/2007-11/30/2009)
  • COENZYME Q10 IN HUNTINGTON'S DISEASE ($97,500.00, 12/01/2007-11/30/2009)
  • RESEARCH ASSOCIATE SERVICES FOR BRIONY CATLOW ($12,000.00, 09/15/2008-09/14/2009)
  • RESEARCH ASSOCIATE SERVICES FOR BRIONY CATLOW ($12,000.00, 09/15/2008-09/14/2009)
  • RESEARCH ASSOCIATE SERVICES FOR KUNYU LI ($13,000.00, 09/01/2008-08/31/2009)
  • RESEARCH ASSOCIATE SERVICES FOR VASYL SAVA ($19,000.00, 09/01/2008-08/31/2009)
  • RESEARCH ASSOCIATE SERVICES FOR VASYL SAVA ($19,000.00, 09/01/2008-08/31/2009)
  • PARKINSON'S DISEASE RESEARCH FUND ($87,981.00, 07/01/2008-06/30/2009)
  • PARKINSON'S DISEASE RESEARCH FUND ($100,000.00, 07/01/2008-06/30/2009)
  • PROTOCOL #DIMOND ($61,362.00, 07/01/2007-12/31/2008)
  • PROTOCOL #DIMOND ($28,048.00, 07/01/2007-12/31/2008)
  • HUNTINGTON'S DISEASE CLINIC - CENTER OF EXCELLENCE ($50,000.00, 10/01/2004-12/31/2008)
  • COOPERATIVE HUNTINGTON'S OBSERVATIONAL RESEARCH TRIAL (COHORT) ($16,000.00, 07/01/2005-06/30/2008)
  • ELLIS ENDOWED CHAIR ($119,042.00, 07/01/2002-06/30/2008)
  • BONE MARROW-MOBILIZING AGENTS FOR ALZHEIMER'S DISEASE ($70,802.00, 03/28/2007-03/27/2008)
  • RESEARCH ASSOCIATE SERVICES: NEUROSCIENCE RESEARCH (VASYL SAVA) ($21,098.00, 02/01/2007-01/31/2008)
  • PROTOCOL #TREND HD, AN01.01.0011, PO #412950-G ($23,848.00, 04/01/2005-01/31/2008)
  • PROTOCOL #TREND HD, AN01.01.0011, PO #412950-G ($74,800.00, 04/01/2005-01/31/2008)
  • HUNTINGTON'S DISEASE CLINIC - CENTER OF EXCELLENCE ($50,000.00, 10/01/2004-12/31/2007)
  • PROTOCOL #DOMINO ($32,000.00, 08/15/2005-08/14/2007)
  • TRIGGERING NEW NEURON PRODUCTION IN ADULT HIPPOCAMPUS WITH NEUROD ($52,004.00, 04/01/2006-07/01/2007)
  • COOPERATIVE HUNTINGTON'S OBSERVATIONAL RESEARCH TRIAL (COHORT) ($16,000.00, 07/01/2005-06/30/2007)
  • THE BRAIN'S DNA REPAIR RESPONSE TO NEUROTOXICANTS ($350,483.00, 07/01/2003-01/31/2007)
  • HUNTINGTON'S DISEASE CLINIC-CENTER OF EXCELLENCE ($50,000.00, 10/01/2004-09/30/2006)
  • HD/412281-G ($47,660.00, 04/01/2003-03/31/2006)
  • HUNTINGTON'S DISEASE CLINIC: CENTER OF EXCELLENCE APPLICATION ($50,000.00, 10/01/2004-09/30/2005)
  • SALARY SUPPORT FOR GENG XIGANG, MD ($24,000.00, 08/01/2004-07/31/2005)
  • THE BRAIN'S DNA REPAIR RESPONSE TO NEUROTOXICANTS ($346,449.00, 07/01/2003-07/31/2005)
  • NEUROSCIENCE RESEARCH LAB: OXYRADICALS & MACROMOLECULAR DAMAGE IN AGING DOPAMINERGIC NEURONS ($28,692.00, 06/01/2003-07/31/2005)
  • PROTOCOL #TETRA-HD/412281-G ($17,530.00, 04/01/2003-06/30/2005)
  • PROTOCOL #TETRA-HD/412281-G ($97,209.00, 04/01/2003-11/30/2004)
  • THE BRAIN'S DNA REPAIR RESPONSE TO NEUROTOXICANTS ($343,327.00, 07/01/2003-07/31/2004)
  • NEUROSCIENCE RESEARCH LAB: OXYRADICALS & MACROMOLECULAR DAMAGE IN AGING DOPAMINERGIC NEURONS ($49,010.00, 06/01/2003-05/31/2004)
  • NEUROSCIENCE RESEARCH LAB: OXYRADICALS & MACROMOLECULAR DAMAGE IN AGING DOPAMINERGIC NEURONS ($40,000.00, 06/01/2003-05/31/2004)
  • NEURAL STEM CELLS FROM UMBILICAL CORD BLOOD ($60,000.00, 09/28/2001-08/31/2002)
  • OXYRADICALS AND MACROMOLECULAR DAMAGE IN AGING DOPAMINE NEURONS ($49,388.00, 07/01/1998-06/30/2002)
  • BONE-MARROW DERIVED HUMAN NEURONAL CELLS ($120,000.00, 10/01/1998-12/31/2001)
  • OXYRADICALS AND MACROMOLECULAR DAMAGE IN AGING DOPAMINE NEURONS ($39,500.00, 07/01/1998-06/30/2001)


    • Lectures
  • "Effects of G-CSF on Mouse Hippocampal Neurogenesis" International Society for Stem Cell Research 7th Annual Meeting . Spain - 2009.
  • "Parkinsons Disease and Fall Risk" 10th Annual VA/USF Falls Conference. FL, United States - 2009.
  • "G-CSF Reduces Brain Amyloid, Increases Expression of Synaptophysin and Improves Cognition in a Mouse Model of Alzheimers Disease" 9th International Conference on Alzheimers Disease Drug Discovery. NY, United States - 2008.
  • "Filgastrim (G-CSF) increases hippocampal neurogenesis" Society for Neuroscience. DC, United States - 2008.

    • Profile last modified on 02/17/2012